Abstract: The anti-PD-L1 antibody (22C3) is used as a companion diagnostic for successful checkpoint inhibitor therapy in head and neck squamous cell carcinoma. The positive predictive value of this assay, however, is less than ideal as a high PD-L1 score does not...
Key Takeaways CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1. Lower levels of ‘M1/anti-tumor’ CD68+ or CD68+CD163– cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163+...
Key Takeaways Image analysis is able to use immune biomarkers to correlate immune cell presence and localization with patient survival in NSCLC. Patient survival correlates with the presence or absence of CD68 and CD163 macrophage markers, but these markers do not...
Background Historically, immunohistochemistry (IHC) assays have been designed for simplicity of manual pathology, however, this is not always ideal to acquire the appropriate data for patient selection and outcomes. Due to various challenges within the current...
In the downloadable original research article sponsored by Pfizer, the digital tissue analysis was performed using the Flagship Biosciences proprietary Image Analysis platform. The article was published in the Journal: Clinical Cancer Research online first on June 3,...
In partnership with Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, Flagship Biosciences published this downloadable original research article. It was first published on Monday, May 10...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Scientist turned business leader will strengthen the company’s commercial operations and bolster business development efforts.BROOMFIELD, CO - March 9, 2023 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the...
We are honored to announce that Flagship Biosciences has earned a Frost & Sullivan 2023 North American Customer Value Leadership Award in the AI-enabled digital pathology solutions market. Following from detailed evaluation of best practices criteria, the award...
Genomenon’s genomic landscapes enhance Flagship’s biomarker services and companion diagnostic development solutionsBroomfield, CO and Ann Arbor, MI – February 7, 2023 – Flagship Biosciences, a leader in spatial biology and biomarker analytics services, today announced...
EVENTS
Visit Flagship at the Spatial Biology for Drug Development Summit. October 11-13, 2023. Join us at the inaugural Spatial Biology for Drug Development Summit to explore implementation strategies, challenges in interpretation, and how this rapidly changing technology is...
Visit us at booth E30 to learn how we can partner for end-to-end support of your research and development program. We help you analyze more data in more depth, so you can produce more effective therapies. Attending the 13th World Clinical Biomarkers & CDx Summit?...
Flagship Bioscience is your source for spatial biology expertise, moving your research forward every step of the way. Our mission is to explore complex biomarkers within the context of disease in order to advance your precision medicine strategy. Attending the 2023...